What VUGENE does

VUGENE, UAB is a Vilnius, Lithuania-headquartered bioinformatics company founded by Juozas Gordevičius that operates as a "Service-as-a-Software" provider of cloud-based multi-omics data analysis for biomedical research and drug discovery. Its core product, the VUGENE Multi-omics Platform, integrates genomics, transcriptomics, epigenomics, proteomics, metabolomics, single-cell, and multi-omics integration workflows, powered by AI/ML-driven pattern recognition, proprietary algorithms such as Persimmon for differentially methylated region detection, batch-effect correction pipelines, and agentic AI systems that automate data extraction and normalization. Across 4+ years of operation the company reports 6,500+ completed projects, 25+ TB of analyzed data, and 30+ peer-reviewed publications.

The company generates revenue primarily through custom, quote-based, multi-year bioinformatics consulting engagements delivered via direct enterprise sales, with stated plans to transition toward a self-serve SaaS model on app.vugene.com. Customers include pharmaceutical companies, biotech firms, contract research organizations, research institutions, hospitals, and individual principal investigators; named logos on the website include Corewell Health, Rush University, Inotiv, Wayne State University, The Clock Foundation, and University of Virginia. Operations span two legal entities: VUGENE UAB (Lithuania, headquarters at Vilnius Tech Park) for non-US territories and VUGENE LLC (Delaware) for US-territory services.

VUGENE's commercial positioning combines domain specialization across all major omics layers with AI/ML customization; it maintains GDPR compliance, a registered data protection officer, and partnerships with Biocrates (metabolomics kits), The Clock Foundation (epigenetic aging clocks with 3,000+ studies to date), and Inotiv (December 2025 strategic collaboration embedding VUGENE's platform in Inotiv's Discovery & Translational Sciences Division). The company holds a 2024 Baltic-American Freedom Foundation Impact Award and was named a Notable Player in Big Data and Analytics by StartUs Insights.

Name

VUGENE

Legal name

VUGENE UAB

Website

https://vugene.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

VUGENE is a Lithuania-based bioinformatics company offering cloud-based multi-omics data analysis (genomics, transcriptomics, proteomics, epigenomics, metabolomics) for pharmaceutical, biotech, CRO, and academic clients in drug discovery and biomedical research.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151), Software Publishers (5132), Computer Systems Design Services (541512)

SIC

Services-Computer Programming, Data Processing, Etc. (7370), Services-Prepackaged Software (7372), Services-Computer Processing & Data Preparation (7374)

akta.pro primary industry

Data Virtualization & Federation (HDAEACAH)

akta.pro secondary industry

Privacy, Consent & Data Governance Compliance (GDPR/CCPA, data lineage) (FSAGAFAI)

Keywords

• Multi-omics analysis
• Bioinformatics services
• Computational biology
• Genomics data analysis
• AI drug discovery

Headquarters

HQ city

Vilnius

HQ country

Lithuania

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Bioinformatics Consulting Services: Service-as-a-Software company providing consulting services in the field of bioinformatic and computational biological research, analysis, and interpretation of data. Customers upload data to the Platform and receive analysis services with results delivered on project milestones.
2. Cloud-Based Platform Access: Future software-as-a-service model where customers will be able to access a VUGENE portal, input their data, discuss outcomes with VUGENE staff or agentic AI, and receive results directly through the platform.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

VUGENE is a Service-as-a-Software company that delivers bioinformatics and multi-omics data analysis services through its cloud-based Multi-omics Platform. Customers upload complex biological datasets (genomic, transcriptomic, epigenomic, proteomic, metabolomic, single-cell) and receive AI/ML-powered analysis, statistical modeling, pathway analysis, and interpretation services on project milestones, with the platform transitioning toward self-service SaaS access.

Product overview

VUGENE is a Service-as-a-Software company offering a cloud-based multi-omics bioinformatics platform that integrates AI and machine learning to transform raw biological data into actionable scientific insights. The core VUGENE Multi-omics Platform serves as the central product, which encompasses individual omics analysis services (Genomics, Transcriptomics, Single-cell, Epigenomics, Metabolomics, Proteomics) and multi-omics integration capabilities. Service modules including Statistics & Interpretation, Machine Learning & AI, and Security & Data Management complement the platform, enabling customers to perform reproducible, automated analysis and interpretation of biomedical research data for drug discovery and precision medicine applications.

Differentiator

Problem solved

Functional benefit

Products and services

• VUGENE Multi-omics Platform Cloud-based bioinformatics platform that transforms raw multi-omics data (genomics, transcriptomics, proteomics, metabolomics, epigenomics, single-cell) into actionable scientific insights, enabling cross-study and cross-platform integration for drug discovery and biomedical research.
• Genomics Analysis Genomics data analysis extracting insights from DNA sequences by identifying and interpreting SNVs, insertions, deletions, and structural variants for population genetics, rare diseases, and cancer genomics applications.
• Transcriptomics Analysis RNA-seq data analysis workflows providing quantification of gene expression, alternative splicing, and other transcribed elements with statistical analysis tailored to complex experimental designs.
• Single-cell Analysis Single-cell data analysis uncovers gene expression and epigenetic landscapes at the individual cell level, providing insights into cellular heterogeneity and disease pathology through identification of rare cell types and tracking of cell differentiation pathways.
• Epigenomics Analysis Epigenetic data analysis examining DNA methylation, histone modifications, and chromatin accessibility to uncover modifications that regulate gene expression without altering the DNA sequence.
• Metabolomics Analysis Comprehensive profiling of targeted or untargeted metabolites to identify and quantify metabolites for elucidating their roles in physiological and pathological processes.
• Proteomics Analysis Comprehensive examination of the protein landscape including identification, quantification, function analysis, and interaction mapping of proteins for understanding cellular processes and disease progression.
• Multi-omics Integration Integration of data from multiple omics experiments providing a comprehensive view of biological systems for discovering therapeutic targets, understanding disease mechanisms, and developing personalized solutions.
• AI/ML-Powered Modeling Services Training and evaluation of predictive models using classical machine learning techniques and cutting-edge deep learning methods, from feature selection to model optimization for reliable and meaningful results.
• Statistics & Interpretation Services Automated workflows handling complex experimental designs with advanced statistical models and pathway searches across multiple databases, delivering publication-ready figures and result summaries.
• Security & Data Management Data security services maintaining customer data within selected global regions via cloud-based platforms or on-premise computational resources for efficient handling of sensitive datasets.

Quantifiable outcome

• 4+ years of operation with 6500+ projects completed and 25+ TB of data analyzed across 30+ publications
• +3 more outcomes

Named customers6 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• InotivcoreStrategic or Co-development Partner · 11 December 2025Strategic collaboration to integrate VUGENE's AI and machine learning solutions into Inotiv's Discovery & Translational Sciences Division. Inotiv will leverage VUGENE's cloud-based bioinformatics platform to analyze complex biological data including epigenomic and proteomic datasets, with the goal of improving prediction of drug efficacy and safety in early-stage research.
• The Clock FoundationcoreStrategic or Co-development PartnerThe Clock Foundation is making epigenetic aging clocks more accessible for use with preclinical and clinical studies. VUGENE collaborates on automated analysis and AI modelling platform development, having performed more than 3000 studies to-date for the foundation.
• Corewell HealthcoreStrategic or Co-development PartnerCollaborative research partnership including a recent longitudinal multi-omics study on pediatric traumatic brain injury that identified the S100A8/A9 complex as a mechanistic driver of neuroinflammation. Multiple joint publications on neurodegeneration and dementia.
• Michigan State UniversityminorStrategic or Co-development PartnerAcademic research partner in collaborative study on pediatric traumatic brain injury applying longitudinal multi-omics approaches.
• University of VirginiaminorStrategic or Co-development PartnerAcademic partner in study on maternal oxytocin treatment effects on offspring epigenetic age, working with VUGENE team on bioinformatics analysis.
• LithuaniaBIOminorOthersVUGENE is a member of LithuaniaBIO, the Lithuanian Biotechnology Association. CEO Gražina Mykolaitytė Nielsen serves as a board member.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• DNAnexus: Cloud-based bioinformatics platform serving pharma, biotech, and clinical customers with multi-omics data management and analysis. Closely comparable to VUGENE on target customer (pharma/biotech), delivery model (cloud platform), and omics scope.
• Velsera (formerly Seven Bridges): Biomedical informatics platform offering multi-omics analysis, clinical genomics, and AI-driven insights to pharma and research institutions. Directly comparable on multi-omics platform, pharma/biotech customer base, and AI/ML-enabled interpretation.
• Lifebit: Cloud genomics and multi-omics platform serving pharma, research consortia, and population genomics programs. Comparable on cloud SaaS delivery for biomedical data analysis and pharma/biotech enterprise customers.
• SOPHiA GENETICS: AI-driven genomics and multi-omics platform used by hospitals, labs, and pharma for clinical and research applications. Comparable on multi-omics analysis, AI/ML for biomarker discovery, and healthcare/pharma customer segments.
• Genuity Science (formerly WuXi NextCODE): Genomics and multi-omics analytics provider offering platform and services for pharma drug discovery and clinical research. Comparable on services + platform model serving pharma/biotech with multi-omics analysis.

Emerging players

• BC Platforms: Genomics and real-world data platform for pharma R&D and precision medicine, focused on data integration across omics and clinical sources. Comparable on multi-omics integration and pharma/RWE target customers, though smaller and more genomics-centric.
• Form Bio: Cloud bioinformatics and multi-omics analysis platform (spin-out from Battelle) offering workflows for genomics, transcriptomics, and epigenomics. Comparable on cloud-delivered multi-omics analysis but focused more on workflow productization than services.

Broad incumbents

• QIAGEN Digital Insights (formerly QIAGEN Bioinformatics): Established bioinformatics product portfolio including Ingenuity Pathway Analysis and CLC Genomics Workbench, serving pharma, academic, and clinical customers. Broad incumbent with overlapping omics analysis capabilities but much larger footprint and broader toolset.
• Illumina BaseSpace Sequence Hub: Cloud ecosystem from the dominant sequencing instrument vendor, providing apps and pipelines for genomics and multi-omics analysis. Broad incumbent leveraging sequencing hardware installed base; overlaps with VUGENE on omics analysis workflows for pharma/biotech.
• Eurofins Genomics: Global genomics and bioinformatics services provider within the larger Eurofins Scientific testing group, offering sequencing, DNA synthesis, and bioinformatics analysis to pharma and academic customers. Broad incumbent with overlapping omics analysis and custom service model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC_xKWW4gR2AQIKVVkkI4Y0g
• LinkedInlinkedin.com/company/vugene

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VUGENE